Celltrion and LISCure Biosciences announce strategic collaboration to develop novel microbiome treatment for Parkinson's disease
Co-research and co-development of novel microbiome therapeutics
Discovery of new candidates to meet high unmet medical needs in Parkinson's disease
SEOUL, South Korea, Feb. 20, 2023 /PRNewswire/ -- LISCure Biosciences Inc., a clinical-stage biotech developing advanced microbiome technology with precision targets, announced a multi-year strategic R&D collaboration with Celltrion to identify novel microbiome therapy for Parkinson's disease.
Under the agreement, Celltrion and LISCure intend to develop oral live biotherapeutic products (LBPs) for Parkinson's disease. LISCure will receive research funding and is eligible to receive additional payments as the project progresses. LISCure will lead discovery of novel candidates and Celltrion will be responsible for further clinical and regulatory development.
Parkinson's disease is known to occur due to a low level of dopamine and abnormal aggregation of ?-synuclein associated with gut dysbiosis, suggesting that microbiome-based therapies are potential therapeutic strategies for novel treatments of Parkinson's disease.
LISCure advances brain-target bacterial exosome technology for neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease based on its platform technology. Celltrion intends to leverage the collaboration to expand its business strategy of microbiome therapy and strengthen neurodegenerative pipeline.
The global market size of Parkinson's disease treatment was valued at USD 3.5 billion in 2019 and is anticipated to reach USD 11.5 billion in 2029 (CAGR=12.6%). The US Parkinson's disease market size was USD 1.8 billion in 2019 (market share = 51.5%)[1].
The National Health IT Collaborative for the Underserved (NHIT), the first and oldest national non-profit focused on equitable access to health technology for underserved communities and communities of color, celebrated its 15th anniversary today...
The "Social Anxiety Disorder (SAD) - Market Insight, Epidemiology and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.
The Social Anxiety Disorder (SAD) market report provides current treatment practices, emerging...
The "Global Continuous Glucose Monitoring Solutions Market, 2027 Forecast" report has been added to ResearchAndMarkets.com's offering.
Technological advancements and strategic partnerships create new opportunities for CGM vendors.
The rising...
Researchers at Kanazawa University report in ACS Nano how ultrathin layers of tin disulfide can be used to accelerate the chemical reduction of carbon dioxide - a finding that is highly relevant for our quest towards a carbon-neutral society....
The "Regenerative Medicines: Bone and Joint Applications" report has been added to ResearchAndMarkets.com's offering.
The global market for regenerative medicine for bone and joint applications was valued at $9.6 billion in 2022.
By technology, this...
The Canadian Animal Health Institute is thrilled to announce the winners of the inaugural ?Cutest Pets on Parliament Hill Contest'. Parliamentarians, Senators, staffers, and members of the Press Gallery on Parliament Hill, submitted more than 65...